This work describes LW-1017, a potent, selective, and brain-penetrant small-molecule TRPML1 agonist and evaluates its pharmacodynamic activity and therapeutic effects in aged preclinical mouse models of Parkinson’s disease (PD) and Alzheimer’s disease (AD), supporting TRPML1 agonism as a promising strategy to counteract age-associated neurodegenerative disease.
Abstract
Age-related decline in autophagy–lysosomal pathway function is a key contributor to the accumulation of toxic protein aggregates, neuroinflammation, and neuronal loss in neurodegenerative diseases. Transient receptor potential mucolipin-1 (TRPML1) is a lysosomal Ca²⁺ channel that coordinates acute lysosomal signaling and MiT/TFE-dependent transcription to promote lysosomal biogenesis, cellular clearance, and neuronal resilience. Despite strong mechanistic rationale, whether pharmacological activation of TRPML1 can therapeutically modulate disease-relevant pathology in vivo has remained unresolved. Here, we describe LW-1017, a potent, selective, and brain-penetrant small-molecule TRPML1 agonist and evaluate its pharmacodynamic activity and therapeutic effects in aged preclinical mouse models of Parkinson’s disease (PD) and Alzheimer’s disease (AD). LW-1017 activated TRPML1-mediated ion conductance and induced concentration-dependent nuclear translocation of TFEB/TFE3/MiTF, leading to coordinated activation of CLEAR network genes. In vivo, oral administration achieved robust central nervous system exposure and produced sustained modulation of lysosomal and autophagy biomarkers, including lipidation of LC3 and GABARAPL1 and induction of lysosome-associated proteins. In an aged α-synuclein–based PD model, LW-1017 dose-dependently reduced pathological α-synuclein, attenuated gliosis, preserved nigrostriatal dopaminergic integrity, and improved motor performance. In an aged amyloid-β oligomer model of AD, LW-1017 reduced amyloid and phosphorylated tau pathology, decreased neuroinflammation, preserved neuronal integrity, and improved cognition. Efficacy was observed at low oral doses (3 mg/kg/day), consistent with efficient brain penetration and target engagement. Together, these findings provide the first in vivo evidence that pharmacological activation of TRPML1 can engage autophagy–lysosomal pathways and ameliorate pathology in aged models of both AD and PD, supporting TRPML1 agonism as a promising strategy to counteract age-associated neurodegenerative disease.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles. Beyond these hallmark pathological features, the complex pathogenesis of AD involves cellular dysfunctions associated with chronic oxidative stress and neuroin...
Song-I. Seol, Ji-Eun Kim, Dashdulam Davaanyam et al.· International Journal of Mol...· 0 citations
Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which microglia-mediated neuroinflammation contributes to disease progression. Icariin (ICA), a major bioactive flavonoid from Epimedium, has neuroprotective activity, but how it regulates mitochondrial quality control and inflammatory injury in mi...
Long-Min Fan, Hai-Tao Jiang, Min Yi et al.· Chinese Journal of Natural M...· 0 citations
Findings establish mild modulation of mtCI as a therapeutic strategy to restore metabolic resilience and identify C273 as a promising disease-modifying candidate for AD treatment.
Sergey Trushin, Thi Kim Oanh Nguyen, Mark Ostroot et al.· npj Drug Discovery· 0 citations
Overall, MA-5 suppresses neuroinflammation and reverses accelerated transcriptomic aging, supporting its potential as a therapeutic strategy for GD and other lysosomal storage disorders, as well as for diseases characterized by mitochondrial dysfunction, chronic inflammation, and pathological accumulation.
Y. Tongu, Tomoko Kasahara, Kohta Nakamura et al.· Research Square· 0 citations
GN is a brain-penetrant preclinical candidate that links ATG16L1-dependent autophagy with α-synuclein clearance and NLRP3 inflammasome suppression in PD models and completely abrogated the neuroprotective and anti-inflammatory effects of GN both in vitro and in vivo.
Cheng-Fu Su, Zhi-Qiang Deng, Ka-Yee Ying et al.· Phytomedicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.